95 related articles for article (PubMed ID: 7278616)
1. Retrospective epidemiological study of hemopoietic system neoplasms in Argentina.
Quiroga Micheo E; Calcagno EJ; Calabria SI; Besuschio SC; Magnasco JH; Sackmann Muriel F; Maccione E; Barros C; Santoro A; de Soto ZC
Medicina (B Aires); 1981; 41(2):187-200. PubMed ID: 7278616
[No Abstract] [Full Text] [Related]
2. [Epidemiology of hemoblastosis].
Gus'kova AK
Probl Gematol Pereliv Krovi; 1979 Feb; 24(2):58-9. PubMed ID: 424405
[No Abstract] [Full Text] [Related]
3. Importance of a specialized registry of haematopoietic malignancies.
Carli PM
Nouv Rev Fr Hematol (1978); 1991; 33(2):119-21. PubMed ID: 1766838
[No Abstract] [Full Text] [Related]
4. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-80: patterns in space and time.
Lickiss JN; Giles GG; Baikie MJ; Lowenthal RM; Challis D; Panton J
J Natl Cancer Inst; 1984 Jun; 72(6):1223-31. PubMed ID: 6587144
[TBL] [Abstract][Full Text] [Related]
5. Residential exposure to electric power transmission lines and risk of lymphoproliferative and myeloproliferative disorders: a case-control study.
Lowenthal RM; Tuck DM; Bray IC
Intern Med J; 2007 Sep; 37(9):614-9. PubMed ID: 17543004
[TBL] [Abstract][Full Text] [Related]
6. [Principles and results of 5 years' work on a register of hemoblastoses].
Lapin BA; Lebedeva IuL; Lebedev VN; Iakovleva LA; Finchenko GA
Vopr Onkol; 1980; 26(1):18-23. PubMed ID: 6444476
[TBL] [Abstract][Full Text] [Related]
7. [Organization and the 1st results of the work of a registry of hemoblastoses].
Lebedeva IuL; Lapin BA; Lebedev VN; Bologov VN; Broun VK
Probl Gematol Pereliv Krovi; 1979 Apr; 24(4):50-7. PubMed ID: 432237
[No Abstract] [Full Text] [Related]
8. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-80: occupational and familial aspects.
Giles GG; Lickiss JN; Baikie MJ; Lowenthal RM; Panton J
J Natl Cancer Inst; 1984 Jun; 72(6):1233-40. PubMed ID: 6587145
[TBL] [Abstract][Full Text] [Related]
9. Myeloproliferative neoplasms: association with lymphoproliferative disorders; a single institution experience.
Batt T; Tegg E; Johnston A
Pathology; 2016 Oct; 48(6):637-9. PubMed ID: 27580959
[No Abstract] [Full Text] [Related]
10. [Morbidity of leukemia and other hemoblastoses in an urban population].
Baziian GV; Podgornykh LK
Vopr Onkol; 1982; 28(7):67-72. PubMed ID: 7101832
[TBL] [Abstract][Full Text] [Related]
11. Cancers of the haematopoietic and lymphatic systems.
Tucker A
Br J Hosp Med; 1977 Jul; 18(1):95-6. PubMed ID: 884381
[No Abstract] [Full Text] [Related]
12. Which paper?
Schofield GB
Br J Hosp Med; 1977 Jul; 18(1):95. PubMed ID: 884380
[No Abstract] [Full Text] [Related]
13. Familial malignant blood disease in the country of Jämtland, Sweden.
Eriksson M; Bergström I
Eur J Haematol; 1987 Mar; 38(3):241-5. PubMed ID: 3595812
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France.
Hausfater P; Cacoub P; Sterkers Y; Thibault V; Amoura Z; Nguyen L; Ghillani P; Leblond V; Piette JC
Am J Hematol; 2001 Jul; 67(3):168-71. PubMed ID: 11391713
[TBL] [Abstract][Full Text] [Related]
15. Socioeconomic/occupational risk factors for lymphoproliferative diseases in Sweden.
Ji J; Hemminki K
Ann Epidemiol; 2006 May; 16(5):370-6. PubMed ID: 16246580
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of antibodies to hepatitis C virus in patients with lymphoproliferative disorders.
Cavanna L; Sbolli G; Tanzi E; Romanò L; Civardi G; Buscarini E; Vallisa D; Berté R; Rossi A
Haematologica; 1995; 80(5):486-7. PubMed ID: 8566896
[No Abstract] [Full Text] [Related]
17. Pretransplant assessment of the risk for posttransplant lymphoproliferative disorder.
Walker RC
Transplant Proc; 1995 Oct; 27(5 Suppl 1):41. PubMed ID: 7482817
[No Abstract] [Full Text] [Related]
18. Posttransplant lymphoproliferative disorders in liver recipients treated with OKT3 or ALG induction immunosuppression.
McAlister V; Grant D; Roy A; Yilmaz Z; Ghent C; Wall W
Transplant Proc; 1993 Feb; 25(1 Pt 2):1400-1. PubMed ID: 8442154
[No Abstract] [Full Text] [Related]
19. Serum levels of vascular endothelial growth factor in chronic leukemias. A comparative study with emphasis on myeloproliferative disorders.
Molica S; Santoro R; Iuliano F; Di Raimondo F; Fichera E; Giustolisi R
Haematologica; 2001 Jul; 86(7):771. PubMed ID: 11454538
[No Abstract] [Full Text] [Related]
20. Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome.
Zipursky A; Brown EJ; Christensen H; Doyle J
Clin Lab Med; 1999 Mar; 19(1):157-67, vii. PubMed ID: 10403079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
